Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

Hematologic Malignancies Clinical Trial

Official title:
Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes Derived From Patients With Bone Marrow Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide Graft-Versus-Host Disease Prophylaxis.

Status Active, not recruiting

Clinical Trial Summary

This Phase 1 clinical study is designed to examine the safety and feasibility of using anti-CD3/CD28 activated marrow infiltrating lymphocytes (MILs) as treatment of relapse after allogeneic hematopoietic cell transplantation (alloHCT) for patients with hematologic malignancies with bone marrow involvement of their relapsed disease. These MILs will be derived from the bone marrow of the relapsed patient who had previously received post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis (PTCy-MILs). A bone marrow aspiration will be performed on the patient to collect ~200ml of marrow for ex vivo expansion. During this expansion process, T cells will be activated and expanded by co-stimulation with anti-CD3/anti-CD28 monoclonal antibodies covalently attached to super-paramagnetic microbeads. Patients will be treated with salvage therapy while this ex vivo expansion is ongoing. After the simultaneous salvage therapy and ex vivo expansion, the activated PTCy-MILs will be reinfused. Patients will be monitored with the primary objective being the feasibility of expanding to targeted dose levels activated PTCy-MILs that do not cause grade III-IV acute GVHD within the first 90 days after PTCy-MIL infusion.

Clinical Trial Description

Primary Objectives: 1. Feasibility of generating activated PTCy-MILs in patients with relapsed disease involving the bone marrow. 2. Toxicity of PTCy-MILs, specifically the rate of grade III-IV acute GVHD within the first 90 days after PTCy-MIL infusion. Secondary Objectives 1. Determination of an optimal safe dose for PTCy-MILs. 2. Immunologic characterization of the PTCy-MIL product before and after expansion. 3. Immune reconstitution after treatment with PTCy-MILs. 4. Incidence and severity of chronic GVHD. 5. Clinical responses (complete remissions, partial remissions, stable disease) as measured by criteria specific for the particular disease type. 6. Progression-free and overall survival. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02342613
Study type	Interventional
Source	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	May 28, 2015
Completion date	March 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05433090` - An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies	N/A
Completed	`NCT00061620` - Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies	Phase 1
Enrolling by invitation	`NCT02473757` - Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Recruiting	`NCT02032446` - Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease	Phase 1/Phase 2
Recruiting	`NCT01203722` - Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT02884375` - Elderly CAncer Patient	N/A
Completed	`NCT00780052` - Infusional C-myb ASODN in Advanced Hematologic Malignancies	Phase 1
Recruiting	`NCT04098393` - Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation	Phase 1
Recruiting	`NCT06028828` - Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation	Phase 2
Completed	`NCT04538599` - RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies	Phase 1
Completed	`NCT03609827` - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed	`NCT01380756` - Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia	Phase 1
Recruiting	`NCT05849207` - Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant	Phase 1
Not yet recruiting	`NCT05028478` - A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT02494258` - A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders	Phase 2
Completed	`NCT03212560` - Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
Active, not recruiting	`NCT02600208` - Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device	Phase 2/Phase 3
Completed	`NCT02145403` - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies	Phase 1/Phase 2
Completed	`NCT01949545` - Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment	Phase 1
Completed	`NCT01930981` - Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life	N/A